시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 관상동맥 질환 시장 보고서(2025년)
Coronary Artery Disease Global Market Report 2025
상품코드 : 1824367
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,457,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,334,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,211,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

관상동맥 질환 시장 규모는 앞으로 몇 년 동안 급성장할 것으로 예측됩니다. 2029년에는 CAGR 10.9%를 나타내 482억 7,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 라이프스타일 요인 증가, 원격의료 및 원격 모니터링의 중시, 인터벤셔널 심장병 수술의 확대, 가치 기반의 헬스케어 모델로의 이행, 신규 약물 요법의 개발 등에 기인한다고 생각됩니다. 예측 기간의 주요 동향으로는 유전자 치료의 개발, 진단에 있어서의 인공지능의 통합, CAD 케어에 있어서의 정신건강에 대한 주목, 재택치료 서비스 증가, 원격 심장 재활의 채용 등을 들 수 있습니다.

향후 5년간의 성장률 10.9%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국 간의 관세의 영향 때문입니다. 무역 마찰은 스웨덴과 일본에서 개발된 분획 혈류 예비량(FFR) 가이드와이어 및 선진 CT 혈관 조영 시스템의 가격을 상승시켜 CAD 발견 지연과 순환기과의 비용 상승을 초래함으로써 미국의 심장 의료에 지장을 초래할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

관상동맥 질환의 보급률이 증가함에 따라 향후 몇 년 동안 관상동맥 질환 시장 성장을 이끌 것으로 예측됩니다. 관상동맥 질환(CAD)은 심장 근육에 혈액을 공급하는 관상동맥의 협착과 폐색을 특징으로하는 병리입니다. CAD 사례 증가는 식생활 변화, 스트레스, 운동 부족, 비만, 노화 및 기타 요인으로 인해 발생합니다. 관상동맥 질환의 치료에는 클로피도그렐, 티카그렐롤, 와파린, 헤파린 등의 약물요법과 관상동맥 우회 이식술, 혈관성형술, 스텐트 유치술 등의 치료가 있습니다. 예를 들어, 2024년 5월 미국에 본사를 둔 보건사회복지부 산하 연방정부기관인 질병대책예방센터(CDC)는 관상동맥성 심질환(CHD)이 심장병의 주요 유형이며 2022년에는 37만 1,506명이 사망했다고 보고했습니다. 20세 이상 성인의 약 5%(20명 중 1명)가 관상동맥 질환(CAD)을 앓고 있습니다. 2022년에는 심혈관 질환(CVD)으로 인한 사망 약 5명 중 1명이 65세 미만 성인에서 발생했습니다. 따라서, 관상동맥 질환의 유병률 증가는 예측 기간 동안 관상동맥 질환 시장을 밀어올릴 것으로 예측됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Coronary artery disease (CAD) is a medical condition affecting the coronary arteries, responsible for supplying oxygen-rich blood to the heart muscle. The disease occurs when these arteries become narrowed or obstructed due to the accumulation of plaque-a buildup of cholesterol, fat, calcium, and other substances.

Primary treatments for coronary artery disease encompass various approaches such as medication, surgical interventions, additional therapies, and other related strategies. Medications include pharmaceutical substances such as clopidogrel, atorvastatin, metoprolol, lisinopril, losartan, amlodipine, nitroglycerin, among others. Diagnosis involves medical procedures such as electrocardiogram (ECG), echocardiogram, stress tests, cardiac catheterization, heart CT scans, and other diagnostic methods. These medications and diagnostic procedures are made available through diverse distribution channels such as hospital pharmacies, retail pharmacies, online pharmacy platforms, and others. The utilization of these treatments and diagnostic measures extends to hospitals, specialty clinics, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The coronary artery disease market research report is one of a series of new reports from The Business Research Company that provides coronary artery disease market statistics, including coronary artery disease industry global market size, regional shares, competitors with a coronary artery disease market share, detailed coronary artery disease market segments, market trends and opportunities, and any further data you may need to thrive in the coronary artery disease industry. This coronary artery disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The coronary artery disease market size has grown strongly in recent years. It will grow from $29.15 billion in 2024 to $31.88 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to prevalence of coronary artery disease, growth in minimally invasive surgeries, increase in sedentary lifestyles, aging population and cad prevalence, evolution of pharmacological treatments.

The coronary artery disease market size is expected to see rapid growth in the next few years. It will grow to $48.27 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to growing lifestyle factors, focus on telemedicine and remote monitoring, expansion of interventional cardiology procedures, shift towards value-based healthcare models, and development of novel drug therapies. Major trends in the forecast period include the development of gene therapies, integration of artificial intelligence in diagnosis, focus on mental health in CAD care, rise in home-based healthcare services, and adoption of remote cardiac rehabilitation.

The forecast of 10.9% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. cardiac care by inflating prices of fractional flow reserve (FFR) guidewires and advanced CT angiography systems developed in Sweden and Japan, resulting in delayed CAD detection and higher cardiology department costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of coronary artery disease is anticipated to drive the growth of the coronary artery disease market in the coming years. Coronary artery disease (CAD) is a medical condition marked by the narrowing or blockage of the coronary arteries, which supply blood to the heart muscle. The rise in CAD cases can be attributed to dietary changes, stress, lack of exercise, obesity, aging, and other factors. Treatment options for coronary artery disease include medications such as clopidogrel, ticagrelor, warfarin, and heparin, as well as procedures like coronary artery bypass grafting, angioplasty, and stenting. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a US-based federal agency under the Department of Health and Human Services, reported that coronary heart disease (CHD) was the leading type of heart disease, resulting in 371,506 deaths in 2022. Approximately 5% of adults aged 20 and older (1 in 20) were affected by coronary artery disease (CAD). In 2022, about 1 in 5 deaths from cardiovascular disease (CVD) occurred in adults under 65 years old. Therefore, the rise in the prevalence of coronary artery disease is expected to boost the coronary artery disease market during the forecast period.

The increasing aging population is expected to drive the growth of the coronary artery disease market in the future. An aging population refers to a demographic shift characterized by a growing proportion of elderly individuals within society over time. This aging demographic significantly contributes to the expansion of the coronary artery disease market, as older individuals are more vulnerable to this condition. For example, in October 2022, a report from the World Health Organization (WHO), a Switzerland-based agency focused on international public health, indicated that one in six people is projected to be 60 or older by 2030 worldwide. By 2050, the global population of individuals aged 60 and above is expected to reach 2.1 billion. Therefore, the rising aging population is driving the coronary artery disease market.

Prominent companies within the coronary artery disease market are directing their efforts toward developing cutting-edge technologies, including AI-based blood tests. These tests leverage artificial intelligence (AI) algorithms for the analysis and interpretation of blood-related data. For instance, in February 2023, Cardio Diagnostics Holdings, a US-based company specializing in AI-based integrated genetic-epigenetic engines, introduced PrecisionCHD. This innovative blood test combines genetic and epigenetic analyses to enable early identification of coronary heart disease. With a sensitivity of over 75% for both men and women, PrecisionCHD employs a machine-learning model derived from the analysis of billions of genomic and epigenomic data points, incorporating epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers.

Major companies in the coronary artery disease market are concentrating on developing innovative products, such as drug-coated balloon catheters, to drive revenue growth. Drug-coated balloon catheters are medical devices utilized in interventional cardiology to treat narrowed or blocked blood vessels, particularly in cases of coronary artery disease or peripheral artery disease. For example, in March 2024, Boston Scientific Corporation, a US-based medical device company, announced that the US Food and Drug Administration (FDA) had approved the AGENT Drug-Coated Balloon (DCB) for the treatment of coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR refers to the obstruction or narrowing of a stented vessel due to plaque or scar tissue. The AGENT DCB provides a specialized treatment option for the challenging issue of in-stent restenosis, addressing a significant unmet medical need. It is specifically designed for treating ISR as well as previously untreated small vessel coronary disease. Currently available in Europe, parts of Asia Pacific, and Latin America, the AGENT DCB offers a targeted solution for these complex cardiovascular conditions.

In April 2023, Abbott Laboratories, a prominent US-based medical devices and healthcare company, completed the acquisition of Cardiovascular Systems Inc. for a total consideration of $890 million. This strategic acquisition is designed to enhance Abbott's capabilities in addressing vascular disease by integrating the innovative solutions developed and commercialized by Cardiovascular Systems Inc. The latter, based in the United States, is a medical device company with a focus on creating and bringing to market advanced treatments for peripheral and coronary artery disease. This move is indicative of Abbott's commitment to expanding its portfolio and strengthening its position in the medical devices sector, particularly in the field of cardiovascular health.

Major companies operating in the coronary artery disease market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Gilead Sciences Inc., Amgen Inc. , Viatris Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Lupin Pharmaceuticals Inc., Wockhardt Ltd., Honya Medical Inc., Idorsia Pharmaceuticals Ltd., Cytokinetics Inc., Kowa Pharmaceuticals America Inc., Sinotau Pharmaceutical Group, HRV Global Life Sciences, Barr Pharmaceuticals Inc., AdvanceCor GmbH, Deutsches Zentrum fur Herz- Kreislauf-Forschung (DZHK) e.V.

North America was the largest region in the coronary artery disease market in 2024. The regions covered in the coronary artery disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the coronary artery disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The coronary artery disease market includes revenues earned by entities by providing coronary angioplasty, coronary artery bypass and heart transplant services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Coronary Artery Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on coronary artery disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for coronary artery disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The coronary artery disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Coronary Artery Disease Market Characteristics

3. Coronary Artery Disease Market Trends And Strategies

4. Coronary Artery Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Coronary Artery Disease Growth Analysis And Strategic Analysis Framework

6. Coronary Artery Disease Market Segmentation

7. Coronary Artery Disease Market Regional And Country Analysis

8. Asia-Pacific Coronary Artery Disease Market

9. China Coronary Artery Disease Market

10. India Coronary Artery Disease Market

11. Japan Coronary Artery Disease Market

12. Australia Coronary Artery Disease Market

13. Indonesia Coronary Artery Disease Market

14. South Korea Coronary Artery Disease Market

15. Western Europe Coronary Artery Disease Market

16. UK Coronary Artery Disease Market

17. Germany Coronary Artery Disease Market

18. France Coronary Artery Disease Market

19. Italy Coronary Artery Disease Market

20. Spain Coronary Artery Disease Market

21. Eastern Europe Coronary Artery Disease Market

22. Russia Coronary Artery Disease Market

23. North America Coronary Artery Disease Market

24. USA Coronary Artery Disease Market

25. Canada Coronary Artery Disease Market

26. South America Coronary Artery Disease Market

27. Brazil Coronary Artery Disease Market

28. Middle East Coronary Artery Disease Market

29. Africa Coronary Artery Disease Market

30. Coronary Artery Disease Market Competitive Landscape And Company Profiles

31. Coronary Artery Disease Market Other Major And Innovative Companies

32. Global Coronary Artery Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Coronary Artery Disease Market

34. Recent Developments In The Coronary Artery Disease Market

35. Coronary Artery Disease Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기